Events
2 minute read

Myriad: The Implications of the U.S. Supreme Court Decision

June 18, 20132:00 pm - 3:00 pmWebinar

June 18, 2013 | 2:00 p.m. ET | IPO Chat Channel Webinar


On June 13, the U.S. Supreme Court ruled in Association for Molecular Pathology v. Myriad that cDNA molecules are eligible for patent protection, but that a sequence of DNA molecules isolated from their natural state is not. That finding of patent-ineligibility contradicts decades of USPTO practice and the long-standing expectation of the biotech industry.

Both sides declared partial victory in the case, and many uncertainties follow the long-awaited ruling. Our panel includes the litigator who represented Myriad in the Supreme Court, a respected biotech patent prosecutor, and the assistant general counsel at a large pharmaceutical company. They will consider such questions as:



  • How many and which existing gene patents will be challenged in post-grant proceedings at the USPTO?
  • Will holders of gene patents seek reissue?
  • What does the decision mean for protein therapeutics, and other products that are arguably “found in nature”?
  • Are claims to isolated polypeptide sequences covering human proteins that are in therapeutic use no longer valid?
  • Where do comparative diagnostic claims stand after both Myriad and Prometheus?

 


Speakers:



  • Gregory Castanias, Jones Day
  • Kevin Noonan, McDonnell Boehnen Hulbert & Berghoff LLP
  • Paul Golian, Bristol-Myers Squibb Company

 


Sponsored by: Intellectual Property Owners Association


Register online at http://www.ipo.org/index.php/events/ip-chat-channel/